p27, 105, 106 p53 germline mutation, 190 p53 mutation, 44, 85, 105, 267 p53, 22, 27, 44, 54, 59, 72, 73, 91, 94, 98-105, 107, 114, 115, 120, 164, 185, 186, 191, 196, 199, 201, 204, 206, 210, 217, 219, 225, 226, 230, 248, 250, 255, 263, 265, 268, 315 Paclitaxel, see taxanes Palliative care, 297, 308, 323 Pancreatic <strong>cancer</strong>, 13, 22, 24, 45, 72, 73, 120, 131, 248, 250, 251, 273, 281, 284 Papanicolaou smear, 88, 167, 216 Papillary thyroid carcinoma, 258 para-Chloro-ortho-toluidine, 35 Passive smoking, see environmental tobacco smoke Patched, 54 PAX8, 259 Peau de chagrin, 268 Penicillium, 44 Peptic ulcer, 131 Perchloroethylene, 85 Peripheral vascular disease, 131 Peritoneum, 34, 124 Pesticides, 34, 35, 42, 43, 44, 45, 137, 140, 189, 238 Petroleum, 36, 40 Peutz-Jegher syndrome, 72, 199, 251 Peutz-Jeghers polyp, 86 P-glycoprotein, see MDR1 Phaeochromocytoma, 72, 268 Pharmaceutical industry, 286 Pharyngeal <strong>cancer</strong>, 24, 29, 30, 34, 57, 62, 65, 131, 154, 232 Phenacetin, 48, 49 Philadelphia chromosome, 244, 245 Phosphoinositide-3-kinase (PI3K), 117 Photofluoroscopy, 176, 195 Phyto-estrogens, 78, 209 Pilocytic astrocytoma, 266 Piroxicam, 152 Pituitary tumour, 85, 278 Platelet derived growth factor (PDGF), 117, 267 Platelet derived growth factor receptor (PDGFR), 123, 267 Platinum derivatives, 285 Platinum drugs, 49, 91, 186, 197, 206, 208, 212, 214, 219, 221, 222, 263, 282, 286 Pleura, 34, 37 PMS1, 73 PMS2, 73 Poly(ADP-ribose)polymerase (PARP), 93 Polychlorinated biphenyls, 35, 42, 45, 140, 228, 248 Polycyclic aromatic hydrocarbons, 25, 27, 33, 38, 45, 46, 63, 91, 138, 139, 228, 230 Polycystic kidney disease, 262 Polymerase chain reaction, 246 Polymorphisms, 31, 66, 80, 90, 111, 185, 209, 235, 324 Polynucleotide kinase (PNK), 93 Population ageing, 320 pRb, 105, 107 Prednisolone, 286, 287 Prednisone, 286 Premalignant lesions, 73, 84, 163, 170, 172, 175, 185, 199, 216, 224 Primary (de novo) glioblastoma, 267 Procarbazine, 48, 50, 241, 282, 283, 286 Progesterone receptors, 291 Progesterone, 85, 191 Prognostic factors, 123, 124, 282 Programmed cell death, see apoptosis 84 Promoter hypermethylation, 101, 105, 186, 250 Promutagenic DNA adducts, 89 Prophylactic vaccination, 144, 148 Prostaglandins, 151, 290 Prostate <strong>cancer</strong> screening, 160 Prostate <strong>cancer</strong>, 12, 35, 62, 73, 77, 85, 105, 111, 120, 121, 154, 160, 208, 221, 278, 281, 284, 286, 291, 324 Prostate-specific antigen, 160, 208 Prostatic intraepithelial neoplasia (PIN), 210 Proteases, 226 Protein kinase B (Akt, PKB), 117 Protein kinase C (PKC), 117 Proteolysis, 191 Proto-oncogene, 84 PTCH, 72, 266, 268 PTEN, 72, 120, 210, 219, 258, 266, 268 Pulmonary heart disease, 131 Pulmonary tuberculosis, 131 Pyridyloxobutylation adducts, 90 Pyrimidine dimer, 91 Pyrrolizidine alkaloids, 44 Q Quitting, see smoking cessation R Rab11, 226 Radiation, 51-55, 141, 253 Radiotherapy, 277, 317 Radon, 36, 37, 52, 184 RAS, 91, 97, 102, 114, 117, 235, 259 RB1, 44, 72, 98, 99, 104, 105, 114, 210, 230, 267 Reactive oxygen species, 86 Recombination, 71 Recombinational repair, 91 Rehabilitation, 292 Renal cell carcinoma, 72, 261, 268 Renal pelvis <strong>cancer</strong>, 85 Replication error, 86 RET, 72, 259 Retinal haemangioblastomas, 268 Retinoblastoma, 71, 72, 98, 104, 105, 265 Retinoic acid, 153, 244, 246 Retinoids, 151, 152, 154 Rho, 122 Rubber manufacture, 34, 35 Rural areas, 40 Subject index 349
S Saccharin, 64, 85 Salicin, 153 Salt, 63, 64, 176, 194, 233 Sarcoma, 72, 268, 281, 284 Schistosoma haematobium, 57, 58, 228, 229 Schwannoma, 268 Secondary <strong>cancer</strong>s, 48 Secondary glioblastoma, 267 Selenium, 209 Seminoma, 212 Senescence, 87 Serum pepsinogen, 177 Shade, 141 Shh, 54 Sigmoidoscopy, 164 Silica, 34 Single nucleotide polymorphisms, 324 Skin <strong>cancer</strong>, 34-37, 39, 41, 49-51, 53, 68, 69, 72, 92-94, 102, 111, 141-143, 154, 255, 268 SMAD gene family, 206 SMAD2, 199 SMAD4, 199 Small cell lung <strong>cancer</strong>, 185, 186, 281 Smoke, 232 Smokeless tobacco, 23, 25, 27 Smoking cessation, 25, 28, 75, 128, 129, 132, 133, 182, 183, 310 Smoking, see tobacco smoke Smooth muscle tumours, 68 Snuff, 22, 233 Soil pollution, 41 Solar radiation, 37 Somatic mutation, 71 Soots, 34 Spinal ependymomas, 268 Spinal tumours, 266 Spiral CT, 185 Squalamine (NHE-3 inhibitor), 123 Squamous cell carcinoma, 53, 68, 72, 141, 142, 152, 167, 182, 185, 215, 216, 223, 230, 232 Stem cell, 240, 241, 244, 286 Steroid hormones, 191 STI-571, 246, 247, 285 STK11, 250, 251 Stomach <strong>cancer</strong>, 25, 29, 36, 42, 57, 58, 61, 63-65, 85, 94, 111, 120, 131, 175, 194, 196, 238, 274, 281, 284 Subependymal giant cell astrocytoma, 268 Subungual fibroma, 268 Sulfur dioxide (SO 2 ), 40, 138 Sulindac, 152 Sunburn, 142, 253 Sunlight, 51, 91, 135, 141, 253 Sunscreens, 141, 152 Surgical implants, 49 Surgical oncology, 272, 314 350 Subject index T T cells, 59, 149, 242, 288, 289 Talc containing asbestiform fibres, 34 Tamoxifen, 48, 49, 151, 153, 156, 192, 218, 282, 286, 291 Taxanes, 186, 282, 283, 285, 286 TCDD, 34 Telemedicine, 276 Telomerase, 108, 206 Telomere, 108 Teniposide, 50 Testicular <strong>cancer</strong>, 60, 85, 208, 273, 281, 318 Testosterone, 85 2,3,7,8-Tetrachlorodibenzo-para-dioxin (TCDD), 34 1,1,2,2-Tetrachloroethane, 138 Tetrachloroethylene, 35 Tetraphthalic acid, 85 TGF-α, 123, 191 TGF-β, 123, 191, 259, 290 TGF βR2, 250 Thioguanine, 283 Thiotepa, 49 Thymidine kinase, 111 Thyroid <strong>cancer</strong>, 51, 52, 72, 257, 268, 273, 284 Thyroidectomy, 273 TNM staging, 191, 124 Tobacco advertising, 131 Tobacco control, 128, 306-310, 313, 323 Tobacco Free Initiative, 308 Tobacco smoke, 12, 21, 37, 91, 94, 128, 134, 140, 183, 228, 233, 248, 261, 308-310, 322 Tobacco, 22, 25, 30, 39, 41, 85, 102, 128, 182, 223, 228, 233, 248, 261, 304, 308-310, 313, 321 Tobacco-specific nitrosamines, 25 Toluene, 40 Topoisomerase, 191, 283, 285 TRAIL, 290 Transforming growth factors, see TGF-α, TGF-β Transgenic mouse models, 113, 288 Transitional cell carcinoma of the urinary tract, 48, 228 Treosulfan, 49 Trichilemmomas, 268 Trichlorobenzene, 35 Trichloroethylene, 35, 138 Trimethylpentane, 85 TSC1, 268 TSC2, 268 Tuberous sclerosis, 268 Tumour antigens, 288-290 Tumour suppressor genes, 71, 73, 84, 86, 91, 96, 98-102, 109, 121, see also p53 TUNEL assay, 116 Turcot syndrome, 268 Tyrosinaemia, 204 U UICC, 306 Ulcerative colitis, 273
- Page 2 and 3:
WORLD HEALTH ORGANIZATION WHO OMS I
- Page 4 and 5:
WORLD CANCER REPORT Editors Bernard
- Page 6 and 7:
CONTENTS Foreword 9 1 The global bu
- Page 8 and 9:
The global burden of cancer Cancer
- Page 10 and 11:
Fig. 1.2 Incidence and mortality of
- Page 12 and 13:
Central and Southern Europe differ
- Page 14 and 15:
Incidence of cancer in South Centra
- Page 16 and 17:
from documentation of disease to a
- Page 18 and 19:
TOBACCO SUMMARY >In addition to lun
- Page 20 and 21:
Fig. 2.3 Smoking by children is inc
- Page 22 and 23:
Cancers positively Sex Standardized
- Page 24 and 25:
PHARMACOLOGICAL APPROACHES TO SMOKI
- Page 26 and 27:
level the dose—response relations
- Page 28 and 29:
lipoprotein-associated cholesterol,
- Page 30 and 31:
Agent Cancer site/cancer Main indus
- Page 32 and 33:
Industry, occupation Cancer site/ca
- Page 34 and 35:
to occupational exposures in develo
- Page 36 and 37:
Air pollutant WHO Air Quality Guide
- Page 38 and 39:
der cancer of the order of 50% is p
- Page 40 and 41:
AFLATOXIN B 1 HEPATITIS VIRUS (chro
- Page 42 and 43:
Fig. 2.30 Correlation between regio
- Page 44 and 45:
MEDICINAL DRUGS SUMMARY > Certain d
- Page 46 and 47:
Drug or drug combination Cancer IAR
- Page 48 and 49:
Agent or substance Cancer site/canc
- Page 50 and 51:
sources of electromagnetic fields [
- Page 52 and 53:
CHRONIC INFECTIONS SUMMARY > Infect
- Page 54 and 55:
Infection Subclinical Mutagenic fac
- Page 56 and 57:
TUMOURS ASSOCIATED WITH HIV/AIDS Ap
- Page 58 and 59:
DIET AND NUTRITION SUMMARY > Up to
- Page 60 and 61:
Fig. 2.54 The age-adjusted mortalit
- Page 62 and 63:
OVERWEIGHT, OBESITY AND PHYSICAL AC
- Page 64 and 65:
IMMUNOSUPPRESSION SUMMARY >Persiste
- Page 66 and 67:
Fig. 2.64 Cancer following immunosu
- Page 68 and 69:
Syndrome Gene Location Cancer site/
- Page 70 and 71:
viduals, confirmation of a gene def
- Page 72 and 73:
REPRODUCTIVE FACTORS AND HORMONES S
- Page 74 and 75:
PHYTO-ESTROGENS AND CANCER PEVENTIO
- Page 76 and 77:
Indicator Number of oral contracept
- Page 79 and 80:
Mechanisms of tumour development Th
- Page 81 and 82:
The stages in tumorigenesis have be
- Page 83 and 84:
PRECURSOR LESIONS IN CHEMOPREVENTIO
- Page 85 and 86:
CARCINOGEN ACTIVATION AND DNA REPAI
- Page 87 and 88:
adducts, a few weeks or months for
- Page 89 and 90:
I Reactive oxygen species Methylati
- Page 91 and 92:
which remove the mismatched bases,
- Page 93 and 94:
Common human oncogenes Many common
- Page 95 and 96:
product of the RB1 gene (pRb) and a
- Page 97 and 98:
ates a molecular bridge between p53
- Page 99 and 100:
potential cancer genes altered thro
- Page 101 and 102:
One of the earliest genes to be ide
- Page 103 and 104:
Regulation of the cell cycle and co
- Page 105 and 106:
CELL-CELL COMMUNICATION SUMMARY > C
- Page 107 and 108:
Connexin genes and tumour suppressi
- Page 109 and 110:
APOPTOSIS SUMMARY > The term apopto
- Page 111 and 112:
Caspase-8 Caspase-3 c-FLIP Procaspa
- Page 113 and 114:
ways. Several options are under inv
- Page 115 and 116:
INVASION AND METASTASIS SUMMARY > T
- Page 117 and 118:
laminin, entactin and also heparan
- Page 119 and 120:
Target Example of agent Comments Ad
- Page 121 and 122:
organs, and to respond to local gro
- Page 123 and 124:
TOBACCO CONTROL SUMMARY > Tobacco-i
- Page 125 and 126:
Region Deaths due to % of total dea
- Page 127 and 128:
ipated, is primarily attributable t
- Page 129 and 130:
smoke. This may be achieved in part
- Page 131 and 132:
there is no evidence for the effica
- Page 133 and 134:
industries, processes and occupatio
- Page 135 and 136:
stoves arises in rural areas of dev
- Page 137 and 138:
Climbing plants on trellis at end r
- Page 139 and 140:
HEPATITIS B VACCINATION SUMMARY > P
- Page 141 and 142:
Fig. 4.17 Chronic active HBV-associ
- Page 143 and 144:
HUMAN PAPILLOMAVIRUS VACCINATION SU
- Page 145 and 146:
Vaccine Site of trial Number of pat
- Page 147 and 148:
prolonged use. Similar drugs, that
- Page 149 and 150:
aspirin and other non-steroidal ant
- Page 151 and 152:
SCREENING FOR BREAST CANCER SUMMARY
- Page 153 and 154:
Fig. 4.35 Cumulative mortality from
- Page 155 and 156:
SCREENING FOR PROSTATE CANCER SUMMA
- Page 157 and 158:
Fig. 4.39 Poster designed for an an
- Page 159 and 160:
is around 10% for cancer (out of ev
- Page 161 and 162:
45 with one positive rehydrated FOB
- Page 163 and 164:
eing based on (i) time trends in th
- Page 165 and 166:
Fig. 4.48 Women at a clinic in Indi
- Page 167 and 168:
SCREENING FOR ORAL CANCER SUMMARY >
- Page 169 and 170:
India will provide useful informati
- Page 171 and 172:
cer incidence following cure of inf
- Page 173 and 174:
100 50 25 10 5 2.5 1 Japan Males Fe
- Page 175 and 176:
Human cancers by organ site Maligna
- Page 177 and 178:
tobacco smoking: age at start, aver
- Page 179 and 180:
diagnosis is usually confirmed by h
- Page 181 and 182:
is frequent and survival rates are
- Page 183 and 184:
Fig. 5.14 Physician reading digital
- Page 185 and 186:
Markers of prognosis in breast canc
- Page 187 and 188:
cer in the contralateral breast (Ch
- Page 189 and 190:
100 50 25 10 5 2.5 1 Japan Chile Po
- Page 191 and 192:
depends on staging. Small intramuco
- Page 193 and 194:
Fig. 5.30 A diet rich in fresh frui
- Page 195 and 196:
ane protein involved in cell adhesi
- Page 197 and 198:
LIVER CANCER SUMMARY > About 560,00
- Page 199 and 200:
Fig. 5.39 A woman in the Gambia pre
- Page 201 and 202:
REFERENCES 1. Ferlay J, Bray F, Par
- Page 203 and 204:
Certain Possible Uncertain Age Andr
- Page 205 and 206:
Management The dramatic division be
- Page 207 and 208:
TUMOUR NORMAL Gastrula PGC 2n Impri
- Page 209 and 210:
CANCERS OF THE FEMALE REPRODUCTIVE
- Page 211 and 212:
Fig. 5.62 Five-year relative surviv
- Page 213 and 214:
Inheritance of high-penetrance gene
- Page 215 and 216:
invasive malignant. Malignant germ
- Page 217 and 218:
OESOPHAGEAL CANCER SUMMARY >Cancer
- Page 219 and 220:
Fig. 5.76 A radiographic view of an
- Page 221 and 222:
with a stent; laser recannulation,
- Page 223 and 224:
Fig. 5.82 Risk of bladder cancer am
- Page 225 and 226:
Partial cystectomy is appropriate f
- Page 227 and 228:
poorly known since hypopharyngeal c
- Page 229 and 230:
Fig. 5.92 Oral leukoplakia with mil
- Page 231 and 232:
LYMPHOMA SUMMARY > Malignant lympho
- Page 233 and 234:
T Fig. 5.101 Nuclear magnetic reson
- Page 235 and 236:
Fig. 5.106 Five-year relative survi
- Page 237 and 238:
Fig. 5.109 The immediate aftermath
- Page 239 and 240:
A B Fig. 5.113 Acute myeloid leukae
- Page 241 and 242:
Fig. 5.118 Five-year relative survi
- Page 243 and 244:
Fig. 5.120 Age-specific incidence a
- Page 245 and 246:
Hereditary condition Mode of inheri
- Page 247 and 248:
MELANOMA SUMMARY > Approximately 13
- Page 249 and 250:
Fig. 5.131 Primary melanoma with a
- Page 251 and 252:
THYROID CANCER SUMMARY > Cancer of
- Page 253 and 254:
Papillary carcinoma RET/PTC TRK BRA
- Page 255 and 256:
KIDNEY CANCER SUMMARY > Cancer of t
- Page 257 and 258:
Stage Clear cell carcinoma Papillar
- Page 259 and 260:
TUMOURS OF THE NERVOUS SYSTEM SUMMA
- Page 261 and 262:
ing the optic tract, brain stem and
- Page 263 and 264:
mut = mutant p53 wt = wildtype p53
- Page 265 and 266:
SURGICAL ONCOLOGY SUMMARY > Surgica
- Page 267 and 268:
Year Radical mastectomy (%) Modifie
- Page 269 and 270:
TELEMEDICINE The prospects for tele
- Page 271 and 272:
Equipment Energy 50% depth dose App
- Page 273 and 274:
CANCER EDUCATION IN MEDICAL COURSES
- Page 275 and 276:
Fig. 6.10 Crystals of cisplatin: mo
- Page 277 and 278:
Responsiveness Cancer (in decreasin
- Page 279 and 280:
Most of the world’s most common c
- Page 281 and 282:
treatment of cancer. The problems l
- Page 283 and 284:
duction. It is clear that tumour ce
- Page 285 and 286:
REHABILITATION SUMMARY > Rehabilita
- Page 287 and 288:
cer and its associated disability.
- Page 289 and 290: REFERENCES 1. Garden FH, Gillis TA
- Page 291 and 292: Cancer pain relief varies and in so
- Page 293 and 294: EMERGING ISSUES IN PALLIATIVE CARE
- Page 295 and 296: Cancer control The negative impact
- Page 297 and 298: priority to cancer control activiti
- Page 299 and 300: Prevention of cancer Every country
- Page 301 and 302: - Assessing the magnitude of the ca
- Page 303 and 304: high-risk women. Further details on
- Page 305 and 306: ecords departments are either rudim
- Page 307 and 308: THE INTERNATIONAL AGENCY FOR RESEAR
- Page 309 and 310: in the capitals/urban areas of four
- Page 311 and 312: in the overall cancer strategy. WHO
- Page 313 and 314: 68% 1955 1975 1995 2025 32% 40% by
- Page 315 and 316: Fig. 7.15 A grandfather at work in
- Page 317 and 318: Fig. 7.17 Main causes of death in d
- Page 319 and 320: Contributors and Reviewers Sources
- Page 321 and 322: Dr Vera Luiz da Costa e Silva Tobac
- Page 323 and 324: Georgia Moore Centers for Disease C
- Page 325 and 326: REVIEWERS Dr Sandra E. Brooks 405 W
- Page 327 and 328: 2.53 T. Norat and E. Riboli, IARC 2
- Page 329 and 330: Gastroenterology, 118(2 Suppl 1): S
- Page 331 and 332: 5.106 & 5.107 IARC/SEER/Osaka Cance
- Page 333 and 334: 4.17 R. Lambert, IARC/Adapted from
- Page 335 and 336: Brain cancer, see nervous system tu
- Page 337 and 338: Fibroblast growth factor (FGF), 117
- Page 339: Microarray, 240 Micronutrients, 65,